[Lani]

ANDI--what I was saying is that historically, the only ways they had of identifying different types of breast cancer which might perhaps behave differently and might perhaps need different treatment were
1) their appearance under the microscope(ductal, lobular, pleiomorphic)
2) there immunohistochemical stain uptake under the microscope (ER,PR, her2)

now they can determine which pathways are active-- EGFR, her2, PI3K, Wnt, mTor,) etc and try to block the 3 most important escape routes. Still a work in progress... but promising route